Keros Therapeutics, Inc. (KROS) financial statements (2022 and earlier)

Company profile

Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E)
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments230,042265,876
Cash and cash equivalents230,042265,876
Receivables18,030172
Prepaid expense993785
Other current assets340160
Other undisclosed current assets2,035733
Total current assets:251,440267,726
Noncurrent Assets
Operating lease, right-of-use asset1,067878
Property, plant and equipment1,335724
Restricted cash and investments1,327115
Other noncurrent assets82 
Total noncurrent assets:3,8111,717
TOTAL ASSETS:255,251269,443
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,9846,761
Accounts payable3,6452,149
Accrued liabilities7,3394,612
Other undisclosed current liabilities862423
Total current liabilities:11,8467,184
Noncurrent Liabilities
Long-term debt and lease obligation231476
Operating lease, liability231476
Liabilities, other than long-term debt 62
Other liabilities 62
Other undisclosed noncurrent liabilities(231) 
Total noncurrent liabilities:231538
Total liabilities:12,0777,722
Stockholders' equity
Stockholders' equity attributable to parent243,174261,721
Common stock22
Additional paid in capital366,927326,730
Accumulated deficit(123,755)(65,011)
Total stockholders' equity:243,174261,721
TOTAL LIABILITIES AND EQUITY:255,251269,443

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues20,100 
Gross profit:20,100 
Operating expenses(76,473)(46,657)
Operating loss:(56,373)(46,657)
Nonoperating income (expense)(360)1,124
Other nonoperating income (expense)(356)160
Interest and debt expense(4) 
Loss from continuing operations before equity method investments, income taxes:(56,737)(45,533)
Other undisclosed income from continuing operations before income taxes4 
Loss from continuing operations before income taxes:(56,733)(45,533)
Income tax expense (benefit)(2,011)172
Net loss available to common stockholders, diluted:(58,744)(45,361)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(58,744)(45,361)
Comprehensive loss, net of tax, attributable to parent:(58,744)(45,361)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: